Adaptimmune Therapeutics PLC Quarterly Costs and Expenses in USD from Q2 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Costs and Expenses history and growth rate from Q2 2015 to Q2 2024.
  • Adaptimmune Therapeutics PLC Costs and Expenses for the quarter ending June 30, 2024 was $59.5M, a 19% increase year-over-year.
  • Adaptimmune Therapeutics PLC Costs and Expenses for the twelve months ending June 30, 2024 was $219M, a 18.6% increase year-over-year.
  • Adaptimmune Therapeutics PLC annual Costs and Expenses for 2023 was $200M, a 4.66% increase from 2022.
  • Adaptimmune Therapeutics PLC annual Costs and Expenses for 2022 was $191M, a 13.5% increase from 2021.
  • Adaptimmune Therapeutics PLC annual Costs and Expenses for 2021 was $168M, a 22.6% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $219M $59.5M +$9.49M +19% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $209M $54.9M +$8.99M +19.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $200M $50.1M +$11.8M +30.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 $188M $54M +$3.96M +7.91% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $184M $50M +$748K +1.52% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $184M $45.9M -$7.61M -14.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $191M $38.3M -$6.01M -13.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 $197M $50M +$6.61M +15.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $191M $49.3M +$6.88M +16.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $184M $53.6M +$15.2M +39.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $168M $44.3M +$5.27M +13.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 $163M $43.4M +$6.32M +17% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $157M $42.4M +$11.7M +37.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $145M $38.3M +$7.8M +25.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $137M $39M +$7.93M +25.5% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 $129M $37.1M -$3.29M -8.15% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $133M $30.8M -$4.9M -13.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $138M $30.5M -$3.27M -9.67% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $141M $31.1M -$2.16M -6.5% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-14
Q3 2019 $143M $40.4M +$6.58M +19.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $136M $35.7M -$2.26M -5.95% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $139M $33.8M -$3.14M -8.51% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $142M $33.2M -$725K -2.13% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $143M $33.8M +$1.63M +5.07% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $141M $37.9M +$10.6M +38.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $130M $36.9M +$11.9M +47.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-06
Q4 2017 $118M $34M +$10.8M +46.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 $108M $32.1M +$11.1M +52.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $96.6M $27.3M +$4.27M +18.6% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $92.3M $25.1M +$5.34M +27% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $87M $23.2M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 $21M +$7.78M +58.7% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 $23M +$9.14M +65.8% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $19.7M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 $13.3M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 $13.9M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.